Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28052675 | 0.80 | NPC1 (0.44) | PRMT6PDE3BPDE3AMAPTNPC1 | |
| SCHEMBL16104947 | 0.76 | KDM4E (0.39) | ERN1NT5EMAPTPTGS2HCAR1 | |
| SCHEMBL30816599 | 0.75 | KDM4E (0.41) | PRMT6PDE3BPDE3AMAPTNPC1 | |
| SCHEMBL16103501 | 0.75 | NT5E (0.36) | ERN1NT5EPTGS2HCAR1 | |
| SCHEMBL16103096 | 0.74 | ERN1 (0.37) | ERN1NPC1RAB9APTGS2POLB | |
| SCHEMBL16057594 | 0.72 | PTGS2 (0.41) | ERN1NT5EPTGS2HCAR1 | |
| SCHEMBL15299351 | 0.71 | NPC1 (0.52) | PRMT6MAPTNPC1RAB9APTGS2 | |
| SCHEMBL3480539 | 0.69 | MAPT (0.46) | PRMT6MAPTNPC1RAB9APTGS2 | |
| SCHEMBL16100497 | 0.69 | ALDH1A1 (0.46) | MAPTPOLBPTGDR2 | |
| SCHEMBL17633620 | 0.69 | NPC1 (0.45) | PRMT6MAPTNPC1RAB9APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2967073-B9 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2967073-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2967073-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| US-9751869-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-05 | — | — | US | disclosed |
| CN-105188380-B | LXR conditioning agents | 百时美施贵宝公司 | 2017-08-15 | — | — | CN | disclosed |
| US-20160289222-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289222-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | US | disclosed |
| EP-2967073-A1 | LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105188380-A | LXR modulators | BRISTOL MYERS SQUIBB CO | 2015-12-23 | — | — | CN | disclosed |
| WO-2014152738-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152738-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289222-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | ERN1 1339/4885PRMT6 2631/4885PDE3B 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.